Figure 3 Proposed algorithm for management of HIV/HCV co‐infected patients with chronic hepatitis C during pegylated‐interferon α2b plus ribavirin therapy. A total of 93% of the non‐responder patients included in the ANRS HC02 RIBAVIC study would discontinue their treatment with an early 100% prediction of non‐response before W24, with 33% detected at W4, 32% at W12 and 28% at W24. All sustained responder patients would have continued their treatment up to W48 but some of them (17.6%) might relapse after the end of treatment; all relapsers were detected by a qualitative HCV RNA positive test by W52 compared to W72 at end of the follow‐up. Similar results were obtained in the interferon α2b plus ribavirin group. *Quantitative assay for HCV RNA was performed when the qualitative test was positive.